2026-09-29 8-K filing
8-K: Item 1.01, Item 3.02, Item 5.03, Item 8.01 D1 +5.9% · since +1.8%
2026-09-15 8-K filing
8-K: Item 8.01, Item 9.01 D1 -5.5% · +5d -1.6%
19 earlier events › 2026-09-14 8-K filing
8-K: Item 8.01, Item 9.01 D1 +5.0% · +5d -8.3%
2026-09-09 Analyst
Jefferies upgrades to Buy D1 +1.5% · +5d -1.4%
2026-09-03 → 09-04 Product Bull
Ivonescimab Shows OS Benefit Over Keytruda in Phase III; SMMT Up 17% China phase III shows significant overall survival benefit over Keytruda, strengthening ivonescimab's profile.
D1 +17.3% · +5d +2.5%
› 2 waves of this story2026-09-03 HARMONi-2 shows ivonescimab OS benefit over pembrolizumab, strengthening first-line NSCLC position2026-09-04 China phase III shows significant overall survival benefit over Keytruda, strengthening ivonescimab's profile.2026-09-03 8-K filing
8-K: Item 8.01, Item 9.01 D1 +17.3% · +5d +2.5%
2026-08-25 → 08-26 Product Bull
SMMT Partner Reports Positive Phase III Results for Ivonescimab in Biliary Tract Cancer HARMONi-GI1 shows significant OS benefit, expanding indication to biliary tract cancer
D1 +4.9% · +5d +6.0%
› 2 waves of this story2026-08-25 Ivonescimab combination extends progression-free survival in lung cancer pts; data published in Lancet Oncol2026-08-26 HARMONi-GI1 shows significant OS benefit, expanding indication to biliary tract cancer2026-08-26 8-K filing
8-K: Item 8.01, Item 9.01 D1 +6.5% · +5d +2.6%
2026-08-25 Analyst
Bernstein upgrades to Market Perform D1 +4.9% · +5d +6.0%
2026-08-12 Analyst
Leerink Partners upgrades to Market Perform D1 -0.1% · +5d -13.2%
2026-08-12 Analyst
SMMT Crosses 50-Day MA; Multiple Analyst Actions on 8/12 Price crossed 50-day MA to $15.73; multiple upgrades/downgrades/initiations on 8/12
D1 -0.1% · +5d -13.2%
2026-08-12 Product Bull
SMMT Partner Ivonescimab Approved by China NMPA for First-Line Squamous NSCLC Partner Akeso announced NMPA approval of ivonescimab plus chemo for first-line squamous NSCLC; SMMT is key developer
D1 -0.1% · +5d -13.2%
2026-08-10 Earnings
Earnings report D1 +6.5% · +5d -14.1%
2026-08-05 8-K filing
8-K: Item 8.01, Item 9.01 D1 -1.7% · +5d +11.6%
2026-07-22 → 07-31 Product Bull
SMMT Upgraded to Hold as FDA Review of Ivonescimab Nears Seeking Alpha upgrades from Sell to Hold; FDA BLA decision for ivonescimab expected by Nov 14, 2026.
D1 +0.8% · +5d -13.2%
› 3 waves of this story2026-07-22 Extended follow-up shows stronger OS advantage for ivonescimab in specific NSCLC; FDA accepted BLA with November PDUFA date2026-07-23 Q2 call highlights survival data, partners with Arcus for kidney cancer, expanding late-stage pipeline2026-07-31 Seeking Alpha upgrades from Sell to Hold; FDA BLA decision for ivonescimab expected by Nov 14, 2026.2026-07-24 Earnings Bear
SMMT Q2 Loss Wider Than Expected, Going Concern Risk Flagged Wider loss with no revenue; company flags going concern risk over cash needs
D1 -8.8% · +5d -4.7%
› 2 waves of this story2026-07-24 Operating expenses $220.5M; loss magnitude vs. expectations to watch2026-07-24 Wider loss with no revenue; company flags going concern risk over cash needs2026-07-24 Earnings Bull
SMMT Reports Q2 Results and Updated Ivonescimab Survival Data Q2 loss widened but beat EPS estimates; ivonescimab advances in late-stage studies and FDA review
D1 -8.8% · +5d -4.7%
› 2 waves of this story2026-07-24 Q2 net loss $215.7M, updated HARMONi OS data, expands into kidney cancer2026-07-24 Q2 loss widened but beat EPS estimates; ivonescimab advances in late-stage studies and FDA review2026-07-23 Earnings
Earnings report D1 +1.6% · +5d -10.3%
2026-07-23 8-K filing
8-K: Item 1.01, Item 9.01 D1 +1.6% · +5d -10.3%
2026-07-22 8-K filing
8-K: Item 8.01, Item 9.01 D1 +0.8% · +5d -13.2%
2026-06-12 Insider buying Bull
Insider buying $100.0M (2) D1 +7.1% · +5d +1.9%
by direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
🙂 Post
Facts and opinions separated · All items sourced · Not investment advice
